NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Public ClinicalTrials.gov record NCT04984811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable disease according to RECIST 1.1. This Phase II study will enroll up to 83 subjects.
Study identification
- NCT ID
- NCT04984811
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2021 (Actual)
- Primary completion
- Aug 28, 2024 (Actual)
- Completion
- Sep 19, 2024 (Actual)
- Last update posted
- Jun 11, 2026
2021 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama | Mobile | Alabama | 36604 | — |
| TOI Clinical Research | Cerritos | California | 90703 | — |
| Eastern CT Hematology & Oncology Associates | Norwich | Connecticut | 06360 | — |
| Florida Cancer Specialists - South Research Office | Fort Myers | Florida | 33916 | — |
| BRCR Medical Center | Plantation | Florida | 33322 | — |
| Florida Cancer Specialists - North Research Office | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists - East Research Office | West Palm Beach | Florida | 33401 | — |
| University Cancer and Blood Center | Athens | Georgia | 30607 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40217 | — |
| Pikeville Medical Center, Inc. | Pikeville | Kentucky | 41501 | — |
| MaineHealth Cancer Care | South Portland | Maine | 04106 | — |
| TidalHealth Peninsula Regional, Inc. | Salisbury | Maryland | 21801 | — |
| Summit Health Medical Center | Florham Park | New Jersey | 07932 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Tennessee Oncology - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| Tennessee Oncology - Nashville | Nashville | Tennessee | 37203 | — |
| Renovatio Clinical - El Paso | El Paso | Texas | 79915 | — |
| Renovatio Clinical - The Woodlands | The Woodlands | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04984811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04984811 live on ClinicalTrials.gov.